Chapter 27 — Key Takeaways

Peptides in Oncology: Hormone-Axis Blockade, Somatostatin Analogs, and Radioligand Therapy

The one thing to remember

Peptides have been standard cancer care for about forty years, and almost nobody outside oncology, urology, endocrinology, and nuclear medicine knows it. The surprise in this chapter is not a frontier. It is how much has been routine, unremarkable, guideline-level medicine for a very long time.

The chapter in nine points

1. The invisibility is explainable, not accidental. The drugs do not sound like peptides (Lupron, Zoladex, Sandostatin); oncology publishes for oncologists; a therapy that has worked since 1985 generates no news; and the consumer peptide market has a direct interest in not mentioning that the pharmaceutical industry built prostate cancer treatment on a peptide. The accurate summary is not "medicine ignored peptides" but "medicine adopted the peptides with a job it could verify."

2. GnRH agonists turn Chapter 3's pulsatility principle into a therapy. The axis reads pattern, not presence. Deliver GnRH continuously instead of in pulses and the receptor desensitizes, gonadotropin output collapses, and testosterone falls to castrate levels. This is androgen deprivation therapy, a mainstay of hormone-sensitive prostate cancer since the mid-1980s.

3. The same principle produces the complication. Before desensitization takes hold, an agonist stimulates — producing a transient testosterone rise, the flare, which can worsen bone pain, urinary obstruction, or spinal cord compression in men with significant disease burden. It is managed with concurrent antiandrogen cover. The flare is not an off-target effect. It is the intended mechanism observed during its first phase — which is why "it works with your body's natural signaling, so it has no side effects" is not an argument.

4. GnRH antagonists suppress without a flare, and came later because they were harder. Blocking a receptor continuously is a more demanding chemistry problem than borrowing the receptor's own desensitization machinery, and early candidates ran into histamine-release reactions. -relin = agonist (surge first); -relix = antagonist (immediate suppression). One letter, opposite initial effect, and a real clinical decision rides on it. Note the precision point: relugolix is oral because it is not a peptide.

5. Octreotide is the stabilization toolkit, deployed in 1988. Native somatostatin lasts minutes. Octreotide is an eight-residue cyclic analog with D-amino acid substitutions and a modified C-terminus — truncation, cyclization, and stereochemistry, all three of Chapter 33's core moves, in an approved drug older than most readers. Lanreotide is a related long-acting analog.

6. Symptom control and tumor control are different claims. Somatostatin analogs control the flushing and diarrhea of carcinoid syndrome — established early, dramatic, patient-reported. They also delay radiographic progression in neuroendocrine tumors — established later, by PROMID and CLARINET, with progression-free endpoints. Two claims, two populations, two endpoints, two ratings. Neither certifies a survival benefit.

7. PRRT makes the peptide an address, not a drug. Many neuroendocrine tumors overexpress somatostatin receptors. Attach a chelator to a somatostatin analog, load it with lutetium-177, and the peptide carries radiation to cells displaying the receptor. The therapeutic agent is the radionuclide. NETTER-1 (2017) established a large progression-free survival benefit in progressive, well-differentiated, receptor-positive midgut tumors. It did not establish an overall survival benefit.

8. Name the pattern: the peptide is not always the drug. Sometimes the peptide is the target (CGRP, Chapter 22). Sometimes it is the substrate you preserve (natriuretic peptides, Chapter 28). Sometimes it is the vehicle (PRRT, here). The role determines what evidence is even relevant.

9. The theranostic loop replaces inference with a photograph. Change only the radionuclide and the same targeting system becomes a diagnostic or a therapy. Image the patient, confirm the target is present in that individual, treat only if it is, then image again to verify delivery. That is patient selection by direct measurement — stronger than anything else in this book. Be precise, though: most clinically important PSMA ligands are small molecules or peptidomimetics, not peptides. The idea transferred beyond peptides, and that transfer is the point.

The payoff

Every successful oncology peptide does one of three jobs:

There is no fourth box. No approved oncology peptide broadly "supports," "modulates," or "optimizes" a healthy system — because that is not a job. It is a description with no endpoint attached, and a field that measures survival in months cannot use it.

The working heuristic: ask what job the peptide has been given, and what measurement would show whether it did the job. Oncology's peptides all have jobs. That is why they are in hospital pharmacies and the others are in email newsletters.

Ratings issued in this chapter

Six ✅ ratings in one chapter is unusual for this book. That is the point.

Dossier progress

Field 7 — Regulatory Status, filled by reading the label rather than by recording a status. Oncology labels are the clearest available demonstration that an approval is a narrow, checkable statement, not a general endorsement: they name tumor type, grade, stage, line of therapy, required prior treatments, and biomarker status. If your Field 7 entry says only "FDA approved," you have recorded a status and lost the content.

What to carry into Chapter 28

Chapter 28 moves to cardiovascular medicine, where the peptide is not always the drug appears again — this time as a peptide you protect rather than a peptide you administer. Watch for it.